ViiV Healthcare Presents Positive Data Showing Vocabria (cabotegravir) and Rekambys (rilpivirine) Can Be Successfully Implemented Across a Range of European Healthcare Settings

LONDON--(BUSINESS WIRE)--Oct 24, 2022--

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer and Shionogi as shareholders, today presented findings from the CARISEL study (Cabotegravir And Rilpivirine Implementation Study in European Locations). The study, which evaluated the perspectives of people living with HIV and healthcare teams through surveys and interviews in addition to evaluating clinical effectiveness, demonstrated that ViiV Healthcare’s Vocabria (cabotegravir injection) and Janssen Pharmaceutical Companies of Johnson and Johnson’s Rekambys (rilpivirine long-acting injectable suspension) was successfully implemented across a range of European healthcare settings. 1 The 12-month findings from the implementation study of the first and only complete long-acting regimen for HIV treatment were presented today at the 30 th HIV Glasgow Conference being held in Glasgow, Scotland and virtually, from 23 – 26 October.

At 12 months, primary findings from the CARISEL study demonstrated that despite most European clinics having no prior long-acting cabotegravir and rilpivirine experience, there was high acceptability, appropriateness, and feasibility among clinic staff towards its implementation (mean scores ≥ 3.8 on a 5-point Likert scale) as well as the long-acting regimen itself (mean scores ≥ 4.2). Of 70 staff participants in the study, 56% reported optimal implementation within one to three months, with 68% of staff participants believing the time spent in clinic was “very” or “extremely acceptable”. 1

Across the duration of the CARISEL study, people living with HIV also found that long-acting cabotegravir and rilpivirine was highly acceptable, appropriate, and feasible to implement (mean scores ≥ 4.47 on a 5-point Likert scale). 1 Long-acting cabotegravir and rilpivirine demonstrated high clinical effectiveness and a low rate of viral failure throughout the duration of the trial.